An aesthetic and wellness clinic in Al Manara with a first-party peptide-therapy consultation page.
Availability does not establish approval or effectiveness. Ask for the exact active ingredient, product registration, indication, prescriber, dispensing source, risks, alternatives, and follow-up plan.
The clinic publicly advertises peptide protocols including compounds that are experimental or not established as approved treatments for the promoted uses. Exact ingredients and registration status should be verified before treatment.
The Nova Clinic's public peptide-therapy page does not list peptide-specific prices.
Ask the clinic for an itemised written quote that identifies the exact product and clinical services included.
Price information is attributed to the clinic and may change. It does not establish medical approval, product registration, effectiveness or the total cost of care.
These labels assess the named molecule, not the clinic’s particular product, protocol or marketing claim. UAE registration remains product and indication specific.
| Peptide | Category | Evidence | Approval note | Editorial assessment |
|---|---|---|---|---|
| BPC-157 | Experimental compound | Preclinical | Not established as an approved human medicine | Most supportive claims rely on laboratory or animal research; robust clinical evidence and established approval are lacking. |
| CJC-1295 | Experimental compound | Limited | Not established as an approved human medicine | Small human studies do not establish broad wellness, anti-ageing or body-composition claims. |
| Ipamorelin | Experimental compound | Limited | Not established as an approved human medicine | Human evidence is limited and does not establish the broad outcomes commonly promoted by clinics. |
| TB-500 | Experimental compound | Preclinical | Not established as an approved human medicine | Commercial claims extend beyond the available human evidence. Product identity and regulatory status require particular caution. |
9:00am–8:00pm, daily
+971 4 384 5666Compare clinical assessment, product traceability, informed consent, monitoring, adverse-event support, and alternatives—not marketing claims.
Is this information outdated? Send the editorial team a correction.Clinics cannot pay to change directory order or evidence classifications.